| Project/Area Number |
18J15051
|
|---|
| Research Category |
Grant-in-Aid for JSPS Fellows
|
| Allocation Type | Single-year Grants |
|---|
| Section | 国内 |
|---|
| Research Field |
Immunology
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
Kumar Alok 京都大学, 医学研究科, 特別研究員(DC2)
|
|---|
| Project Period (FY) |
2018-04-25 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥1,900,000 (Direct Cost: ¥1,900,000)
Fiscal Year 2019: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2018: ¥1,000,000 (Direct Cost: ¥1,000,000)
|
|---|
| Keywords | PD-1 / Immunosupression / PGC-1alpha / Biomarker / Mitochondrial activation / biomarker / cancer immunotherapy |
|---|
| Outline of Annual Research Achievements |
We classified unresponsiveness reasons into i). unresponsvieness because of local reasons ii). unresponsiveness because of having systemic immunosuppressive property (SIP). In addition, we found immune response after PD-1 blockade is associated with mitochondrial activation. Based on this result, we concluded that mitochondrial activation could be biomarker to identify responder and nonresponders. Further, we found SIP-positive tumors release non-proteinaceous small molecule that inhibit mitochondrial activation and proliferation of T cells. Bezafibrate when used alongwith culture superntant cancels the suppressive effect of supernatnat. Bezafibrate treatment alongwith PD-1 blockade enhances the survival of host bearing SIP-positive tumor compared to PD-1 blockade alone.
|
| Research Progress Status |
令和元年度が最終年度であるため、記入しない。
|
| Strategy for Future Research Activity |
令和元年度が最終年度であるため、記入しない。
|
